A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya

A highly effective malaria vaccine remains the ultimate tool for malaria control and elimination. The front runner is RTS,S/AS01, a recombinant protein comprising portions of Plasmodium falciparum (Pf) circumsporozoite protein (CSP). However, the observed vaccine efficacy to clinical malaria in children living in malaria endemic settings is only 36%. In order to understand how to improve upon this vaccine, a comprehensive evaluation of baseline and cumulative factors that impede malaria vaccine performance, in direct contrast to factors associated with protection from malaria, is needed. Stronger correlates of protection based on functional antibody activity has been recently defined using a systems serology approach. To date, these system serology studies have been conducted only for adults from non-endemic regions. Drawing on the WHO Malaria Vaccine Implementation Program in a high- transmission region in Kenya, an intensive longitudinal cohort study design will be employed to follow children during their 4-dose RTS,S vaccination schedule, with active and passive follow-up for Pf infections and episodes of clinical malaria until they reach 4 years of age. The overall hypothesis will be tested by the following specific aims: SA1: To comprehensively characterize baseline and peri-vaccination factors that correlate with vaccine hyporesponsiveness. Using an integrated systems immunology and machine learning approach, the project will determine the effects of ongoing exposures to malaria, systemic inflammation, pre- existing anti-malarial immunity, and immaturity of cellular immune signatures on RTS,S vaccine hypo- responsiveness, defined as the inability to develop a core group of functional anti-CSP antibodies. SA2: To comprehensively characterize the post-vaccination immune signatures in children that correlate with protection from malaria. Using a systems immunology approach, the project will determine the function of vaccine- elicited anti-CSP antibodies and their correlation with age, cellular immune signatures, and protection from malaria. Functional in vitro studies will assess antibody opsonization of sporozoites and antibody-dependent cellular cytotoxicity with and without innate immune cells; assess the phenotype and function of vaccine- elicited CSP-specific T cells; and explore the potential for epigenetic modifications of monocytes (trained immunity) to influence vaccine performance. Using a computational modeling/machine learning approach, the project will integrate deep immunoprofiling features to predict correlates with protection from malaria. Together, this study aims to inform the next generation of malaria vaccines and vaccination programs that could include immune-modulatory components or recommendations to combine antimalarial prophylaxis/treatment within the vaccine schedule.

Project details

Monitoring & Evaluation
Vaccines (Immune Correlates)

Feb 2022 — Jan 2027

$1.98M

Kenya